Teva Pharmaceutical Industries Ltd

Latest stories

4d
Business Wire
武田公佈2015會計年度三個季度(4-12月)的業績,再次確認全年的管理層指引4月至12月的結果再次肯定管理層全年指引 武田成長動力的貢獻 創新型新產品的成長抵消了喪失獨家權益的影響 2015會計年度全年預測顯示,營業利潤升級,其
武田公佈2015會計年度三個季度(4-12月)的業績,再次確認全年的管理層指引
Business Wire / Posted 4 days ago
4月至12月的結果再次肯定管理層全年指引 武田成長動力的貢獻 創新型新產品的成長抵消了喪失獨家權益的影響 2015會計年度全年預測顯示,營業利潤升級,其他未變 再次確認2015會計年度的管理層指引 武田總裁兼執行長Christophe... Read more
28 related stories
4d
Business Wire
武田公布2015财年三个季度(4-12月)的业绩,再次确认全年的管理层指引4月至12月的结果再次肯定管理层全年指引 武田成长动力的贡献 创新型新产品的增长抵消了丧失独家权益所带来的影响 效率增益得以持续 2015财年全年预测
武田公布2015财年三个季度(4-12月)的业绩,再次确认全年的管理层指引
Business Wire / Posted 4 days ago
4月至12月的结果再次肯定管理层全年指引 武田成长动力的贡献 创新型新产品的增长抵消了丧失独家权益所带来的影响 效率增益得以持续 2015财年全年预测显示,运营利润升级,其他未变 再次确认2015财年的管理层指引 武田总裁兼首席执行官Christophe... Read more
28 related stories
4d
National Post
Story | Business Wire News Releases | News | Financial PostLe redressement se poursuit grâce aux moteurs de croissance de Takeda : la gast
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 4 days ago
Le redressement se poursuit grâce aux moteurs de croissance de Takeda : la gastroentérologie, l’oncologie et les marchés émergents OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO : 4502) : Les résultats de la période... Read more
443 related stories
5d
National Post
Story | Business Wire News Releases | News | Financial PostContinues Turnaround with Takeda's Growth Drivers: Gastroenterology, Oncology a
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 5 days ago
Continues Turnaround with Takeda's Growth Drivers: Gastroenterology, Oncology and Emerging Markets OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502): Results of April to December period reaffirms full-year management... Read more
5d
Business Wire
Takeda Reports Results for Three Quarters (April-December) of FY2015, Reaffirms Management Guidance for the Full YearResults of April to December period reaffirms full-year management guidance Co
Takeda Reports Results for Three Quarters (April-December) of FY2015, Reaffirms Management Guidance for the Full Year
Business Wire / Posted 5 days ago
Results of April to December period reaffirms full-year management guidance Contribution of Takeda's growth drivers Growth of innovative new products to offset loss of exclusivity impact Efficiency gains continue For FY2015 full year reported... Read more
6d
National Post
Story | Business Wire News Releases | News | Financial PostAgreement Further Supports Teva’s Novel Biologics Development Program JERUSALE
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 6 days ago
Agreement Further Supports Teva’s Novel Biologics Development Program JERUSALEM & VANCOUVER, British Columbia--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and AbCellera have entered into a collaborative research... Read more
7d
Channel NewsAsia
US appeals court ruling may clear barrier to generic OxyContinREUTERS: A federal appeals court ruled Monday that four patents related to Purd
US appeals court ruling may clear barrier to generic OxyContin
Channel NewsAsia / Posted 7 days ago
REUTERS: A federal appeals court ruled Monday that four patents related to Purdue Pharma's painkiller OxyContin are invalid, potentially bringing Teva Pharmaceutical Industries Ltd and others a step closer to introducing generic versions of the... Read more
11d
Business Wire
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA™ (bendamustine hydrochloride) InjectionJERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industri
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA™ (bendamustine hydrochloride) Injection
Business Wire / Posted 11 days ago
JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced today the commercial availability of BENDEKA™, (bendamustine hydrochloride)... Read more
12d
Business Wire
Fitch Affirms Cardinal Health at 'BBB+' Outlook StableCHICAGO--(BUSINESS WIRE)--Fitch Ratings has affirmed the ratings for Cardinal H
Fitch Affirms Cardinal Health at 'BBB+' Outlook Stable
Business Wire / Posted 12 days ago
CHICAGO--(BUSINESS WIRE)--Fitch Ratings has affirmed the ratings for Cardinal Health, Inc. (NYSE: CAH), including the Long-term Issuer Default Rating (IDR) at 'BBB+' and Short-term IDR at 'F2'. The Rating Outlook is Stable. A full list of rating... Read more
5 related stories
25d
Investopedia
How Allergan Plc Makes Money (AGN,PFE,TEVA,CAH)Allergan, Plc (AGN) is one of the newest and largest corporations in existence.
How Allergan Plc Makes Money (AGN,PFE,TEVA,CAH)
Investopedia / Posted 25 days ago
Allergan, Plc (AGN) is one of the newest and largest corporations in existence. The $123 billion company was established in June 2015, one of the latest stages on a complicated journey. A journey that isn’t over yet, as the company is set to purchase... Read more
m
Business Wire
Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP InhibitorJERUSALEM & NEW YORK--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYS
Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor
Business Wire / Posted 1 months ago
JERUSALEM & NEW YORK--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Checkpoint Therapeutics, Inc. (“Checkpoint”), a Fortress Biotech (NASDAQ: FBIO) Company, announced today a license agreement in which Checkpoint will... Read more

People in this news